Back to home
REGULATORYApril 14, 2026·7 min read
ACC Issues First Scientific Statement on Gene Editing for Heart Disease
The American College of Cardiology publishes its 2026 scientific statement on gene editing therapy for cardiovascular disease, covering CRISPR-based approaches to PCSK9, TTR amyloidosis, and hypertrophic cardiomyopathy. A formal signal that cardiology's regulatory framework is catching up to the science.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.